Reading view
DarkPatterns-LLM: A Multi-Layer Benchmark for Detecting Manipulative and Harmful AI Behavior
Lessons from Neuroscience for AI: How integrating Actions, Compositional Structure and Episodic Memory could enable Safe, Interpretable and Human-Like AI
Why AI Safety Requires Uncertainty, Incomplete Preferences, and Non-Archimedean Utilities
Enhancing Medical Data Analysis through AI-Enhanced Locally Linear Embedding: Applications in Medical Point Location and Imagery
When Algorithms Manage Humans: A Double Machine Learning Approach to Estimating Nonlinear Effects of Algorithmic Control on Gig Worker Performance and Wellbeing
AI-Generated Code Is Not Reproducible (Yet): An Empirical Study of Dependency Gaps in LLM-Based Coding Agents
The body is not there to compute: Comment on "Informational embodiment: Computational role of information structure in codes and robots" by Pitti et al
Viability and Performance of a Private LLM Server for SMBs: A Benchmark Analysis of Qwen3-30B on Consumer-Grade Hardware
Multi-agent Self-triage System with Medical Flowcharts
Taming Data Challenges in ML-based Security Tasks: Lessons from Integrating Generative AI
Generating Verifiable Chain of Thoughts from Exection-Traces
Modeling hepatocellular carcinoma and its microenvironment on a chip
Cell Death Discovery, Published online: 29 December 2025; doi:10.1038/s41420-025-02917-8
Modeling hepatocellular carcinoma and its microenvironment on a chipMetabolic signatures in gastroenteropancreatic neuroendocrine neoplasms: unraveling diagnostic and prognostic insights
Front Endocrinol (Lausanne). 2025 Dec 11;16:1676021. doi: 10.3389/fendo.2025.1676021. eCollection 2025.
ABSTRACT
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of tumors characterized by diverse biological behaviors and variable clinical outcomes. Recent advances have highlighted the important role of metabolic reprogramming in tumorigenesis, progression, and therapeutic resistance in GEP-NENs. In this review, we synthesize the current evidence on metabolic biomarkers and altered metabolic pathways-particularly those involving glucose, lipid, and amino acid metabolism. Key biomarkers such as GLUT-1, FASN, and enzymes involved in ferroptosis, cholesterol biosynthesis, and amino acid catabolism demonstrate strong associations with tumor aggressiveness, hypoxia, and mTOR signaling. Moreover, metabolomic profiling and functional studies suggest that metabolic markers may inform prognosis and predict response to targeted therapies such as Everolimus. Although promising, the clinical translation of these markers is still limited and requires further validation in large, subtype-specific cohorts. Our findings highlight the importance of integrating metabolic profiling into the diagnostic and therapeutic landscape of GEP-NENs. Future research should prioritize biomarker standardization, multi-omics integration, and the development of metabolism-based therapeutic strategies tailored to tumor subtype and differentiation grade.
PMID:41458541 | PMC:PMC12738315 | DOI:10.3389/fendo.2025.1676021